Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Consortium of Multiple Sclerosis Centers (CMSC) and Spire Learning. CMSC is accredited by the ACCME to provide continuing medical education for physicians.
CMSC designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
Nurses: This activity is offered through the joint providership of Nurse Practitioner Alternatives (NPA), CMSC, and Spire Learning. NPA is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
NPA designates this enduring activity for a maximum of 1.0 contact hours of continuing education for nurses and nurse practitioners.
CONFLICTS OF INTEREST STATEMENT
According to the disclosure policies of CMSC and NPA, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.
Scott Newsome, DO
Advisory Board/Consultant: Biogen Idec; Genzyme, a Sanofi Company
Research: Principal Investigator for clinical trials: Biogen Idec and Novartis Pharmaceuticals Corporation, and funds are paid to his institution
June Halper, MSN, APN-C, MSCN, FAAN
Consultant (research activity): Biogen Idec
Corey Ford, MD, PhD, serves as the Chair of the Continuing Professional Education Committee at The Consortium of Multiple Sclerosis Centers (CMSC) and discloses the following relationships:
Consulting Agreements: Biogen Idec; Novartis Pharmaceuticals Corporation; Teva Pharmaceuticals
Sources of Funding for Research: Biogen Idec; Elan; EMD Serono, Inc; Genentech, a member of the Roche Group; Genzyme, a Sanofi Company; Janssen Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation; Ono Pharmaceutical Co, Ltd; Sanofi US; Teva Pharmaceuticals
Nurse Practitioner Alternatives (NPA)
Laurie Scudder, DNP, NP, has served as nurse planner for this activity and has disclosed no relevant financial relationships.
Educational Planning Committee
The Consortium of Multiple Sclerosis Centers (CMSC)
June Halper, MSN, APN-C, MSCN, FAAN, is a consultant to Biogen Idec for a research activity.
Shareholder (spouse/partner): Johnson & Johnson; Procter & Gamble
Kashemi Rorie, PhD
Nothing to disclose with regard to commercial support DISCLAIMER
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the CMSC, NPA, or Spire Learning. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should critically appraise the information presented and draw conclusions only after careful consideration of all available scientific information. OFF-LABEL STATEMENT
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. Levels of Evidence
Levels of evidence are provided for any patient care recommendations made during this presentation. Level A (randomized controlled trial/meta-analysis):
High-quality, randomized controlled trial (RCT) that considers all important outcomes. High-quality meta-analysis (quantitative systematic review) using comprehensive search strategies. Level B (other evidence):
A well-designed, nonrandomized clinical trial. A nonquantitative systematic review with appropriate search strategies and well-substantiated conclusions. Includes lower-quality RCTs, clinical cohort studies and case-controlled studies with nonbiased selection of study participants and consistent findings. Other evidence, such as high-quality, historical, uncontrolled studies, or well-designed epidemiologic studies with compelling findings, is also included. Level C (consensus/expert opinion):
Consensus viewpoint or expert opinion
Each rating is applied to a single reference in the presentation, not the entire body of evidence on the topic.
Sponsorship Statement: This educational activity is jointly provided by the Consortium of Multiple Sclerosis Centers (CMSC), Nurse Practitioner Alternatives (NPA), and Spire Learning.
Support Statement: This activity is supported by independent, unrestricted educational grants from Acorda Therapeutics, Inc; Allergan, Inc; Biogen Idec; and Teva Pharmaceuticals.
COURSE VIEWING REQUIREMENTS
|Supported Browsers: |
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above
For video playback, install the latest version of Flash or Quicktime.